A Multicenter, Open-Label, 2-Stage, Phase 1, Clinical Safety, Pharmacokinetic, And Pharmacodynamic Study Of CVX-045, A Thrombospondin-1 Mimetic, Anti-Angiogenic Agent, In Patients With Advanced Solid Tumors

Trial Profile

A Multicenter, Open-Label, 2-Stage, Phase 1, Clinical Safety, Pharmacokinetic, And Pharmacodynamic Study Of CVX-045, A Thrombospondin-1 Mimetic, Anti-Angiogenic Agent, In Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2010

At a glance

  • Drugs PF 4856882 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Dec 2010 Actual end date changed from Dec 2010 to Nov 2010 as reported by ClinicalTrials.gov.
    • 10 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Jul 2010 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top